Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kapil Bhalla

Showing results (101-110 of 153) with videos related to

Pageof 16
Sort By:
Cancer Research|November 17, 2005
Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycinFei Guo, Kathy Rocha, Purva Bali, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 2024
Editor's Note: Superior Efficacy of a Combined Epigenetic Therapy against Human Mantle Cell Lymphoma CellsWarren Fiskus, Rekha Rao, Ramesh Balusu, et al.
Cancer Chemotherapy and Pharmacology|July 27, 2015
Clinical pharmacology characterization of RG7112, an MDM2 antagonist, in patients with advanced solid tumorsAmita Patnaik, Anthony Tolcher, Murali Beeram, et al.
Blood|June 23, 2010
Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound β-phenylethyl isothiocyanateYumin Hu, Weiqin Lu, Gang Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 31, 2012
Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cellsWarren Fiskus, Rekha Rao, Ramesh Balusu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2006
A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignanciesFrancis Giles, Thomas Fischer, Jorge Cortes, et al.
Blood|July 29, 2008
Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cellsWarren Fiskus, Rekha Rao, Pravina Fernandez, et al.
International Journal of Molecular Sciences|September 22, 2017
Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid LeukemiaMaliha Khan, Jorge Cortes, Tapan Kadia, et al.
Antioxidants (Basel, Switzerland)|April 23, 2022
Targeting the NRF2/HO-1 Antioxidant Pathway in FLT3-ITD-Positive AML Enhances Therapy EfficacySankaranarayan Kannan, Mary E Irwin, Shelley M Herbrich, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 4, 2011
Histone deacetylase inhibitor LAQ824 augments inflammatory responses in macrophages through transcriptional regulation of IL-10Hongwei Wang, Fengdong Cheng, Karrune Woan, et al.
Pageof 16

Showing results (101-110 of 153) with videos related to

Sort By:
Pageof 16
Cancer Research|November 17, 2005
Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycinFei Guo, Kathy Rocha, Purva Bali, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 2024
Editor's Note: Superior Efficacy of a Combined Epigenetic Therapy against Human Mantle Cell Lymphoma CellsWarren Fiskus, Rekha Rao, Ramesh Balusu, et al.
Cancer Chemotherapy and Pharmacology|July 27, 2015
Clinical pharmacology characterization of RG7112, an MDM2 antagonist, in patients with advanced solid tumorsAmita Patnaik, Anthony Tolcher, Murali Beeram, et al.
Blood|June 23, 2010
Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound β-phenylethyl isothiocyanateYumin Hu, Weiqin Lu, Gang Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 31, 2012
Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cellsWarren Fiskus, Rekha Rao, Ramesh Balusu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2006
A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignanciesFrancis Giles, Thomas Fischer, Jorge Cortes, et al.
Blood|July 29, 2008
Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cellsWarren Fiskus, Rekha Rao, Pravina Fernandez, et al.
International Journal of Molecular Sciences|September 22, 2017
Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid LeukemiaMaliha Khan, Jorge Cortes, Tapan Kadia, et al.
Antioxidants (Basel, Switzerland)|April 23, 2022
Targeting the NRF2/HO-1 Antioxidant Pathway in FLT3-ITD-Positive AML Enhances Therapy EfficacySankaranarayan Kannan, Mary E Irwin, Shelley M Herbrich, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 4, 2011
Histone deacetylase inhibitor LAQ824 augments inflammatory responses in macrophages through transcriptional regulation of IL-10Hongwei Wang, Fengdong Cheng, Karrune Woan, et al.
Pageof 16